JD Health's stock surged 5.01% during intraday trading, driven by positive financial results and technological advancements.

The rally follows a research report from Bank of China International which highlighted that JD Health's revenue grew 25% year-over-year last quarter, with its adjusted net profit margin reaching a record high of 10.6%. The brokerage subsequently raised its target price for the stock from HK$45 to HK$47 and maintained a Buy rating.

Further bolstering investor sentiment was the company's announcement of an upgrade to its self-developed medical large language model to version 2.0. The enhanced model incorporates multimodal perception and deep retrieval technology to build a clinical decision support system. This system offers AI-powered diagnostic tools, including tongue diagnosis, assisted diagnosis, and follow-up management, aimed at improving primary care efficiency.